Soo-Mee Bang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Soo-Mee Bang has a total of 505 co-authors. Here are the top co-authors by number of shared publications:
Jeong-Ok Lee
24 shared publications- Jeong-Ok Lee
Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam, Korea
21 shared publications Ji Yun Lee
Department of Internal Medicine Seoul National University Bundang Hospital Seoul National University College of Medicine Seongnam South Korea
20 shared publicationsJee Hyun Kim
Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Gumi-ro 173 Beon- gil, Bundang-gu, Seongnam-Si, Gyeonggi-do, 13620, Korea
13 shared publicationsKeun-Wook Lee
Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Gumi-ro 173 Beon- gil, Bundang-gu, Seongnam-Si, Gyeonggi-do, 13620, Korea
13 shared publicationsYu Jung Kim
Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Gumi-ro 173 Beon- gil, Bundang-gu, Seongnam-Si, Gyeonggi-do, 13620, Korea
13 shared publications
Latest Publications
- Open Access
- 1 January 2027
- Published by XMLink in Journal of Korean Medical Science
- Vol. 42
Increased Arterial Thromboembolism During the Omicron-Onward Wave of COVID-19 in Korea: A Single-Center Retrospective Study Comparing With the Up-to-Delta Periods
Jeong EJ, et al. J Korean Med Sci. 2027 Jan;42:e23. https://doi.org/10.3346/jkms.2027.42.e23
- 1 January 2027
- Published by XMLink in Journal of Korean Medical Science
- Vol. 42
Open AccessIncreased Arterial Thromboembolism During the Omicron-Onward Wave of COVID-19 in Korea: A Single-Center Retrospective Study Comparing With the Up-to-Delta Periods
Jeong EJ, et al. J Korean Med Sci. 2027 Jan;42:e23. https://doi.org/10.3346/jkms.2027.42.e23
- Open Access
- 7 September 2026
- Published by Wiley in Hematological Oncology
- Vol. 44 (5) , e70244
Comparison of Thiotepa, Busulfan, and Cyclophosphamide Versus Busulfan and Thiotepa Conditioning Regimens in Autologous Stem Cell Transplantation for Primary CNS Lymphoma: A Multicenter Retrospective Analysis
Autologous stem cell transplantation (ASCT) with thiotepa‐based conditioning has replaced whole‐brain radiotherapy as consolidation for primary central nervous system lymphoma (PCNSL), providing improved efficacy and reduced neurotoxicity. However, the optimal thiotepa‐containing regimen remains undefined. We retrospectively analyzed patients aged ≤ 60 years who underwent ASCT with thiotepa–busulfan–cyclophosphamide (TBC) or busulfan–thiotepa (BuTT) conditioning after high‐dose methotrexate–based induction at two Korean institutions between 2015 and 2023. Propensity score matching (PSM; n = 20 per group) was performed to adjust for baseline differences. Sixty‐seven patients were included (TBC, n = 30; BuTT, n = 37). TBC was associated with significantly longer progression‐free survival (PFS) from induction (3‐year: 89.9% vs. 72.1%, p = 0.034) and from transplantation (89.9% vs. 69.2%, p = 0.032); overall survival did not differ significantly. In multivariable Cox regression adjusted for pre‐transplant response and cumulative MTX exposure, BuTT was independently associated with inferior PFS (HR 4.09, 95% CI 1.27–13.18, p = 0.019). After PSM, TBC retained superior PFS (84.7% vs. 73.3%, p = 0.035), with a non‐significant trend in Cox analysis (HR 0.22, 95% CI 0.05–1.03, p = 0.054). TBC was associated with delayed engraftment and more grade ≥ 3 non‐hematologic toxicities, but no treatment‐related mortality occurred. In younger patients with PCNSL, TBC demonstrated a trend toward more durable disease control than BuTT, with manageable toxicity. As the thiotepa dose represents the major distinction between regimens, dose‐intensified thiotepa strategies with adjusted partner agents merit further prospective investigation.
- 7 September 2026
- Published by Wiley in Hematological Oncology
- Vol. 44 (5) , e70244
Open AccessComparison of Thiotepa, Busulfan, and Cyclophosphamide Versus Busulfan and Thiotepa Conditioning Regimens in Autologous Stem Cell Transplantation for Primary CNS Lymphoma: A Multicenter Retrospective Analysis
Autologous stem cell transplantation (ASCT) with thiotepa‐based conditioning has replaced whole‐brain radiotherapy as consolidation for primary central nervous system lymphoma (PCNSL), providing improved efficacy and reduced neurotoxicity. However, the optimal thiotepa‐containing regimen remains undefined. We retrospectively analyzed patients aged ≤ 60 years who underwent ASCT with thiotepa–busulfan–cyclophosphamide (TBC) or busulfan–thiotepa (BuTT) conditioning after high‐dose methotrexate–based induction at two Korean institutions between 2015 and 2023. Propensity score matching (PSM; n = 20 per group) was performed to adjust for baseline differences. Sixty‐seven patients were included (TBC, n = 30; BuTT, n = 37). TBC was associated with significantly longer progression‐free survival (PFS) from induction (3‐year: 89.9% vs. 72.1%, p = 0.034) and from transplantation (89.9% vs. 69.2%, p = 0.032); overall survival did not differ significantly. In multivariable Cox regression adjusted for pre‐transplant response and cumulative MTX exposure, BuTT was independently associated with inferior PFS (HR 4.09, 95% CI 1.27–13.18, p = 0.019). After PSM, TBC retained superior PFS (84.7% vs. 73.3%, p = 0.035), with a non‐significant trend in Cox analysis (HR 0.22, 95% CI 0.05–1.03, p = 0.054). TBC was associated with delayed engraftment and more grade ≥ 3 non‐hematologic toxicities, but no treatment‐related mortality occurred. In younger patients with PCNSL, TBC demonstrated a trend toward more durable disease control than BuTT, with manageable toxicity. As the thiotepa dose represents the major distinction between regimens, dose‐intensified thiotepa strategies with adjusted partner agents merit further prospective investigation.
- Open Access
- 12 June 2026
- Published by Elsevier in Research and Practice in Thrombosis and Haemostasis
- Vol. 10 (5)
Risks of Anticoagulation Discontinuation After First VTE in Inherited Thrombophilia: A Long-term Cohort Study
- 12 June 2026
- Published by Elsevier in Research and Practice in Thrombosis and Haemostasis
- Vol. 10 (5)
Open AccessRisks of Anticoagulation Discontinuation After First VTE in Inherited Thrombophilia: A Long-term Cohort Study
- Open Access
- 8 June 2026
- Published by Springer Nature in Annals of Hematology
- Vol. 105 (9)
Thrombosis in adult primary immune thrombocytopenia in Korea: incidence and risk factors in a 20-year retrospective cohort
Background: Immune thrombocytopenia (ITP) is primarily a bleeding disorder, yet thrombotic events occur and remain challenging to predict, particularly in Asian populations and across real-world treatment patterns. We evaluated thrombosis incidence and associated clinical and therapy-related factors in Korean adults with primary ITP. Methods: We conducted a retrospective cohort study of adults (≥ 19 years) with hematologist-confirmed primary ITP at Seoul National University Bundang Hospital from April 1, 2003 to December 31, 2023. Thrombotic events were identified by diagnostic codes and confirmed by review of imaging and clinical documentation. Patients were classified into five ever-treated groups: never treated (Group 1), first-line only (Group 2), immunosuppressive agents without TPO-RA (Group 3), TPO-RA monotherapy (Group 4), and TPO-RA combination therapy (Group 5). Incidence rates were calculated per 100 person-years (PY). Predictors were assessed using Firth’s penalized logistic regression. Results: Among 1,038 patients (median age 57 years; 42.6% male), median follow-up was 1.4 years (IQR, 0.3–4.5) with 3,185 PY. Fourteen patients experienced thrombotic events (19 total; 4 arterial, 15 venous), yielding an incidence of 0.44 per 100 PY (95% CI, 0.24–0.74). No events occurred in never-treated patients; events occurred only in Groups 2–5 ( p < 0.001). In multivariable analysis, atrial fibrillation (OR 6.01), splenectomy (OR 6.97), and higher ordinal treatment-intensity group (OR 2.16 per step) were independently associated with thrombosis (all p ≤ 0.027). Conclusion: Thrombosis was uncommon overall but clustered in high-risk contexts—atrial fibrillation, post-splenectomy status, and higher treatment-intensity patterns, particularly TPO-RA–based regimens. The association between treatment intensity and thrombosis most likely reflects a higher-risk clinical context—including refractory disease, greater inflammatory burden, and more intensive clinical surveillance—rather than a direct causal effect of therapy. These findings support individualized risk assessment, integrating comorbidity profiles and treatment trajectories during periods of therapy escalation and platelet instability.
- 8 June 2026
- Published by Springer Nature in Annals of Hematology
- Vol. 105 (9)
Open AccessThrombosis in adult primary immune thrombocytopenia in Korea: incidence and risk factors in a 20-year retrospective cohort
Background: Immune thrombocytopenia (ITP) is primarily a bleeding disorder, yet thrombotic events occur and remain challenging to predict, particularly in Asian populations and across real-world treatment patterns. We evaluated thrombosis incidence and associated clinical and therapy-related factors in Korean adults with primary ITP. Methods: We conducted a retrospective cohort study of adults (≥ 19 years) with hematologist-confirmed primary ITP at Seoul National University Bundang Hospital from April 1, 2003 to December 31, 2023. Thrombotic events were identified by diagnostic codes and confirmed by review of imaging and clinical documentation. Patients were classified into five ever-treated groups: never treated (Group 1), first-line only (Group 2), immunosuppressive agents without TPO-RA (Group 3), TPO-RA monotherapy (Group 4), and TPO-RA combination therapy (Group 5). Incidence rates were calculated per 100 person-years (PY). Predictors were assessed using Firth’s penalized logistic regression. Results: Among 1,038 patients (median age 57 years; 42.6% male), median follow-up was 1.4 years (IQR, 0.3–4.5) with 3,185 PY. Fourteen patients experienced thrombotic events (19 total; 4 arterial, 15 venous), yielding an incidence of 0.44 per 100 PY (95% CI, 0.24–0.74). No events occurred in never-treated patients; events occurred only in Groups 2–5 ( p < 0.001). In multivariable analysis, atrial fibrillation (OR 6.01), splenectomy (OR 6.97), and higher ordinal treatment-intensity group (OR 2.16 per step) were independently associated with thrombosis (all p ≤ 0.027). Conclusion: Thrombosis was uncommon overall but clustered in high-risk contexts—atrial fibrillation, post-splenectomy status, and higher treatment-intensity patterns, particularly TPO-RA–based regimens. The association between treatment intensity and thrombosis most likely reflects a higher-risk clinical context—including refractory disease, greater inflammatory burden, and more intensive clinical surveillance—rather than a direct causal effect of therapy. These findings support individualized risk assessment, integrating comorbidity profiles and treatment trajectories during periods of therapy escalation and platelet instability.
- Open Access
- 29 January 2026
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
- Vol. 111 (7) , 2417-2424
Metabolic syndrome and risk of monoclonal gammopathy of undetermined significance: a large Korean cohort study
Monoclonal gammopathy of undetermined significance (MGUS) is a premalignant plasma cell disorder with a risk of progression to multiple myeloma. Metabolic syndrome (MetS) is implicated in cancer development, yet its association with MGUS remains unclear. We examined MetS as a risk factor for MGUS in a large Korean cohort. In a retrospective cohort study using the National Health Information Database, we analyzed 4,453,504 adults undergoing health checkups in 2012, followed through 2022. MetS was defined by NCEP-ATP III criteria. Over a median 9.3-year follow-up, 1,241 MGUS cases were identified. MetS was associated with a 28% increased MGUS risk (HR: 1.28, 95% CI: 1.14-1.44). Risk escalated with more MetS components, peaking at 76% for five components (HR: 1.76, 95% CI: 1.35-2.30). Low HDL cholesterol, hypertension, and central obesity were key risk factors, with higher risks in males and younger adults (20–39 years). Longitudinal analysis showed MetS onset (HR: 1.25, 95% CI: 1.06-1.47) or persistence (HR: 1.25, 95% CI: 1.06-1.48) increased MGUS risk compared to persistent MetS absence, whereas MetS resolution showed no significant risk increase over persistent MetS absence. MetS increases MGUS risk, particularly in males and younger individuals. Resolving MetS may mitigate MGUS risk, supporting targeted metabolic interventions.
- 29 January 2026
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
- Vol. 111 (7) , 2417-2424
Open AccessMetabolic syndrome and risk of monoclonal gammopathy of undetermined significance: a large Korean cohort study
Monoclonal gammopathy of undetermined significance (MGUS) is a premalignant plasma cell disorder with a risk of progression to multiple myeloma. Metabolic syndrome (MetS) is implicated in cancer development, yet its association with MGUS remains unclear. We examined MetS as a risk factor for MGUS in a large Korean cohort. In a retrospective cohort study using the National Health Information Database, we analyzed 4,453,504 adults undergoing health checkups in 2012, followed through 2022. MetS was defined by NCEP-ATP III criteria. Over a median 9.3-year follow-up, 1,241 MGUS cases were identified. MetS was associated with a 28% increased MGUS risk (HR: 1.28, 95% CI: 1.14-1.44). Risk escalated with more MetS components, peaking at 76% for five components (HR: 1.76, 95% CI: 1.35-2.30). Low HDL cholesterol, hypertension, and central obesity were key risk factors, with higher risks in males and younger adults (20–39 years). Longitudinal analysis showed MetS onset (HR: 1.25, 95% CI: 1.06-1.47) or persistence (HR: 1.25, 95% CI: 1.06-1.48) increased MGUS risk compared to persistent MetS absence, whereas MetS resolution showed no significant risk increase over persistent MetS absence. MetS increases MGUS risk, particularly in males and younger individuals. Resolving MetS may mitigate MGUS risk, supporting targeted metabolic interventions.
- Open Access
- 15 January 2026
- Published by Korean Cancer Association in Cancer Research and Treatment
- Vol. 58 (1) , 311-319
Validating the Korean Geriatric Assessment Tool in Elderly Multiple Myeloma Patients: A Multicenter Study
Purpose This study evaluates the Korean Cancer Study Group Geriatric Score-7 (KG-7) frailty screening tool’s effectiveness in elderly multiple myeloma (MM) patients to prevent under and overtreatment.Materials and Methods This prospective pilot cohort study included 100 elderly patients aged 70 and older with newly diagnosed MM who had not undergone transplantation from August 2020 to January 2022.Results The median age was 77 years, and 73.0% of patients were classified at International Staging System stages 2 or 3. Using a 5-point cutoff on the KG-7 index (non-frail, score ≥ 5; frail, score < 5), 31% were categorized as frail. After a median follow-up of 26.8 months, the 3-year overall survival rate was 73.0%. There was no statistically significant association between any frailty index and the risk of death. However, frail patients defined by the simplified frailty index (hazard ratio [HR], 2.49; 95% confidence interval [CI], 1.09 to 5.95; p=0.030) and by KG-7 (HR, 2.43; 95% CI, 1.03 to 5.86; p=0.043) had a significantly higher risk of grade 3-4 non-hematologic toxicity, whereas the International Myeloma Working Group definition did not. Over a 24-month tracking period, vulnerability as measured by KG-7 either improved or deteriorated.Conclusion The pilot study, which had a limited number of participants, did not demonstrate KG-7’s effectiveness in predicting survival; however, it successfully predicted severe non-hematologic toxicities. We plan to conduct larger studies in elderly MM patients to determine whether KG-7 can help tailor their treatment regimens.
- 15 January 2026
- Published by Korean Cancer Association in Cancer Research and Treatment
- Vol. 58 (1) , 311-319
Open AccessValidating the Korean Geriatric Assessment Tool in Elderly Multiple Myeloma Patients: A Multicenter Study
Purpose This study evaluates the Korean Cancer Study Group Geriatric Score-7 (KG-7) frailty screening tool’s effectiveness in elderly multiple myeloma (MM) patients to prevent under and overtreatment.Materials and Methods This prospective pilot cohort study included 100 elderly patients aged 70 and older with newly diagnosed MM who had not undergone transplantation from August 2020 to January 2022.Results The median age was 77 years, and 73.0% of patients were classified at International Staging System stages 2 or 3. Using a 5-point cutoff on the KG-7 index (non-frail, score ≥ 5; frail, score < 5), 31% were categorized as frail. After a median follow-up of 26.8 months, the 3-year overall survival rate was 73.0%. There was no statistically significant association between any frailty index and the risk of death. However, frail patients defined by the simplified frailty index (hazard ratio [HR], 2.49; 95% confidence interval [CI], 1.09 to 5.95; p=0.030) and by KG-7 (HR, 2.43; 95% CI, 1.03 to 5.86; p=0.043) had a significantly higher risk of grade 3-4 non-hematologic toxicity, whereas the International Myeloma Working Group definition did not. Over a 24-month tracking period, vulnerability as measured by KG-7 either improved or deteriorated.Conclusion The pilot study, which had a limited number of participants, did not demonstrate KG-7’s effectiveness in predicting survival; however, it successfully predicted severe non-hematologic toxicities. We plan to conduct larger studies in elderly MM patients to determine whether KG-7 can help tailor their treatment regimens.
- Open Access
- 1 January 2026
- Published by XMLink in Journal of Korean Medical Science
- Vol. 41
Real-World Outcomes of Letermovir Prophylaxis in Allogeneic Hematopoietic Stem Cell Transplantation: Implications for Extended Prophylaxis Strategies
Kim SA, et al. J Korean Med Sci. 2026 Dec;41:e330. https://doi.org/10.3346/jkms.2026.41.e330
- 1 January 2026
- Published by XMLink in Journal of Korean Medical Science
- Vol. 41
Open AccessReal-World Outcomes of Letermovir Prophylaxis in Allogeneic Hematopoietic Stem Cell Transplantation: Implications for Extended Prophylaxis Strategies
Kim SA, et al. J Korean Med Sci. 2026 Dec;41:e330. https://doi.org/10.3346/jkms.2026.41.e330
- 18 October 2025
- Published by Taylor & Francis in Expert Review of Hematology
- Vol. 19 (2) , 117-119
Reassuring clinicians and patients using SGLT-2 inhibitors: is there a need to worry about blood complications?
- 18 October 2025
- Published by Taylor & Francis in Expert Review of Hematology
- Vol. 19 (2) , 117-119
Reassuring clinicians and patients using SGLT-2 inhibitors: is there a need to worry about blood complications?
- Open Access
- 10 July 2025
- Published by Springer Nature in Cardiovascular Diabetology
- Vol. 24 (1) , 1-10
Prevalence and thrombotic risk of SGLT-2 inhibitor-associated erythrocytosis: a retrospective cohort study
Background: Sodium-glucose cotransporter 2 (SGLT-2) inhibitors, widely used for type 2 diabetes and cardiorenal conditions, may induce erythrocytosis, potentially increasing cardiovascular risk. This study investigates its prevalence, risk factors, and thrombotic implications. Methods: In a single-center retrospective study, we analyzed 6787 patients prescribed SGLT-2 inhibitors (2014–2024). Erythrocytosis was defined as hemoglobin > 16.5 g/dL or hematocrit > 49% in men, > 16.0 g/dL or > 48% in women. We assessed prevalence, risk factors, and thrombotic events using logistic regression. Results: Erythrocytosis occurred in 1145 patients (16.9%) over a median follow-up of 530 days (IQR, 277–981), with a median hemoglobin rise of 1.0 g/dL (IQR, 0.4–1.8). Male sex (OR 3.24, 95% CI 2.47–4.26), BMI ≥ 25 kg/m2 (OR 1.97, 95% CI 1.63–2.39), and current smoking (OR 2.41, 95% CI 1.96–2.96) significantly increased risk (all p < 0.001), while age ≥ 70 years, hypertension, dyslipidemia, and chronic kidney disease were associated with reduced risk. Thrombosis was rare (0.5%, 33 patients) and associated with antiplatelet use (OR 3.57, 95% CI 1.60–7.97), anticoagulant use (OR 5.93, 95% CI 2.60–13.57), and baseline erythrocytosis (OR 3.75, 95% CI 1.41–9.96). Among 33 patients with thrombosis, five exhibited erythrocytosis at the time of the event and within the prior six months; all had arterial thrombosis associated with underlying conditions (atrial fibrillation, coronary calcification, atherosclerosis), not directly attributable to SGLT-2-induced erythrocytosis. Conclusions: SGLT-2 inhibitors are associated with a 16.9% prevalence of erythrocytosis, but thrombotic risk appears primarily driven by pre-existing conditions. Graphical
- 10 July 2025
- Published by Springer Nature in Cardiovascular Diabetology
- Vol. 24 (1) , 1-10
Open AccessPrevalence and thrombotic risk of SGLT-2 inhibitor-associated erythrocytosis: a retrospective cohort study
Background: Sodium-glucose cotransporter 2 (SGLT-2) inhibitors, widely used for type 2 diabetes and cardiorenal conditions, may induce erythrocytosis, potentially increasing cardiovascular risk. This study investigates its prevalence, risk factors, and thrombotic implications. Methods: In a single-center retrospective study, we analyzed 6787 patients prescribed SGLT-2 inhibitors (2014–2024). Erythrocytosis was defined as hemoglobin > 16.5 g/dL or hematocrit > 49% in men, > 16.0 g/dL or > 48% in women. We assessed prevalence, risk factors, and thrombotic events using logistic regression. Results: Erythrocytosis occurred in 1145 patients (16.9%) over a median follow-up of 530 days (IQR, 277–981), with a median hemoglobin rise of 1.0 g/dL (IQR, 0.4–1.8). Male sex (OR 3.24, 95% CI 2.47–4.26), BMI ≥ 25 kg/m2 (OR 1.97, 95% CI 1.63–2.39), and current smoking (OR 2.41, 95% CI 1.96–2.96) significantly increased risk (all p < 0.001), while age ≥ 70 years, hypertension, dyslipidemia, and chronic kidney disease were associated with reduced risk. Thrombosis was rare (0.5%, 33 patients) and associated with antiplatelet use (OR 3.57, 95% CI 1.60–7.97), anticoagulant use (OR 5.93, 95% CI 2.60–13.57), and baseline erythrocytosis (OR 3.75, 95% CI 1.41–9.96). Among 33 patients with thrombosis, five exhibited erythrocytosis at the time of the event and within the prior six months; all had arterial thrombosis associated with underlying conditions (atrial fibrillation, coronary calcification, atherosclerosis), not directly attributable to SGLT-2-induced erythrocytosis. Conclusions: SGLT-2 inhibitors are associated with a 16.9% prevalence of erythrocytosis, but thrombotic risk appears primarily driven by pre-existing conditions. Graphical
- Open Access
- 15 April 2025
- Published by Korean Cancer Association in Cancer Research and Treatment
- Vol. 57 (2) , 612-620
The Role of Direct Oral Anticoagulants in Managing Myeloproliferative Neoplasms Patients
Purpose Thrombosis and bleeding significantly affect morbidity and mortality in myeloproliferative neoplasms (MPNs). The efficacy and safety of direct oral anticoagulants (DOACs) in MPN patients remain uncertain.Materials and Methods We conducted a large, retrospective, nationwide cohort study using the Korean Health Insurance Review and Assessment Service database from 2010 to 2021.Results Out of the 368 MPN patients included in the final analysis, 62.8% were treated with DOACs for atrial fibrillation (AF), and 37.2% for venous thromboembolism (VTE). The AF group was statistically older with higher CHA2DS2-VASc (congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke, transient ischemic attack, or thromboembolism, vascular disease, age 65-74 years, sex category [female]) scores compared to the VTE group. Antiplatelet agents were used in 51.1% of cases, and cytoreductive drugs in 79.3%, with hydroxyurea being the most common (64.9%). The median follow-up was 22.3 months, with 1-year cumulative incidence rates of thrombosis and bleeding at 11.1% and 3.7%, respectively. Multivariate analysis identified CHA2DS2-VASc scores ≥ 3 (hazard ratio [HR], 3.48), concomitant antiplatelet use (HR, 2.57), and cytoreduction (HR, 2.20) as significant thrombosis risk factors but found no significant predictors for major bleeding.Conclusion Despite the limitations of retrospective data, DOAC treatment in MPN patients seems effective and has an acceptable bleeding risk.
- 15 April 2025
- Published by Korean Cancer Association in Cancer Research and Treatment
- Vol. 57 (2) , 612-620
Open AccessThe Role of Direct Oral Anticoagulants in Managing Myeloproliferative Neoplasms Patients
Purpose Thrombosis and bleeding significantly affect morbidity and mortality in myeloproliferative neoplasms (MPNs). The efficacy and safety of direct oral anticoagulants (DOACs) in MPN patients remain uncertain.Materials and Methods We conducted a large, retrospective, nationwide cohort study using the Korean Health Insurance Review and Assessment Service database from 2010 to 2021.Results Out of the 368 MPN patients included in the final analysis, 62.8% were treated with DOACs for atrial fibrillation (AF), and 37.2% for venous thromboembolism (VTE). The AF group was statistically older with higher CHA2DS2-VASc (congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke, transient ischemic attack, or thromboembolism, vascular disease, age 65-74 years, sex category [female]) scores compared to the VTE group. Antiplatelet agents were used in 51.1% of cases, and cytoreductive drugs in 79.3%, with hydroxyurea being the most common (64.9%). The median follow-up was 22.3 months, with 1-year cumulative incidence rates of thrombosis and bleeding at 11.1% and 3.7%, respectively. Multivariate analysis identified CHA2DS2-VASc scores ≥ 3 (hazard ratio [HR], 3.48), concomitant antiplatelet use (HR, 2.57), and cytoreduction (HR, 2.20) as significant thrombosis risk factors but found no significant predictors for major bleeding.Conclusion Despite the limitations of retrospective data, DOAC treatment in MPN patients seems effective and has an acceptable bleeding risk.